Clinical Trial

Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)

Name: Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION) — clinical trial record (NCT07684235)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

The primary objective of this trial is to evaluate the long-term efficacy, safety, and tolerability of maridebart cafraglutide in participants with obesity or overweight. Trial 20250197 is an extension of trial 20210181 (NCT06858839).

Trial Details

NCT Number	NCT07684235
Lead Sponsor	Amgen
Conditions	Obesity, Overweight
Enrollment	3,200 participants
Start Date	2026-07-29
Primary Completion	2027-12-26 (estimated)
Study Completion	2028-03-19 (estimated)
Updated on ClinicalTrials.gov	2026-07-06